Biomarker ID | 58 |
PMID | 15609297 |
Year | 2005 |
Biomarker | GalNAc-T3 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated (4.6 fold) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(GALNT3):-O-glycan biosynthesis,O-linked glycosylation of mucins, Post-translational protein modif,Protein met,Interleukin-2 signaling pathwayabolismication |
Experiment | Prostate Cancer Vs benign prostatic hyperplasia |
Type of Biomarker | Diagnostic |
Cohort | 18 patients with prostate cancer and 35 patients with Benign Prostatic Hyperplasia (BPH) were tested against these 4 biomarkers to see how easily these 2 groups could be distinguished from one another |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.005 |
Method Used | RT-PCR |
Clinical | No |
Remarks | The ratios of gene expression/10^5 copies of β2-microglobulin were calculated, in samples of PCa and BPH tissues. GALNT3 expression was also calculated by immunohistochemistry of 5 BPH and 5 PCa Patients |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | GALNT3 |